In the realm of cell-based therapies and antibodydrug conjugates (ADCs), CT041, a CLDN18.2-targeted CAR-T product, is being studied in gastrointestinal cancers (NCT04404595), while enfortumab vedotin, targeting Nectin-4, is under investigation for metastatic castration-resistant prostate cancer (NCT04754191)
GHRH-pathway peptides like Sermorelin work upstream of the pituitary, preserving your own production capacity and creating a more physiologic pulse pattern
Regular Monitoring: We track your progress and adjust the treatment as necessary
TRaQ-GmGold was calibrated to measure the absolute GSH concentration of specific subcellular compartments in living cells
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis
Who Should Use Liposomal Glutathione